We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toRegister

DIA 2018 Global Annual Meeting

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.


Registration fees

The prices below are industry pricing. Reduced pricing may be available for Nonprofit/Academia and Government, subject to eligibility verification. Click Register to get pricing appropriate for your work setting. Review the cancellation and transfer policy.

Early Bird:
List Price:
Member Price:



  • #20: Real World Evidence Studies to Evaluate the Safety and Effectiveness of Therapeutic Interventions – Is the Data Fit for Purpose and How Will You Know? $415
  • #21: The IDMP Challenge: Points to Consider for Pharmacovigilance Departments $415
  • #22: Protocol Co-Design with Patients and Advocates $415
  • #23: R&D QA Comprehensive Quality Strategy: An Approach to Managing Quality Risks Throughout the Drug Development Lifecycle $415
  • #24: Preparing for a US FDA Advisory Committee Meeting $415
  • #25: Precedent: A Driver of Regulatory Strategy $415
  • #27: The Evolving Role of Payers in Drug Development: Pricing, Pharmacoeconomics, and Health Technology Assessment $415
  • #28: Preparing Documents for Disclosure and Public Sharing $415
  • #29: Leadership: How to Organize and Lead People in a Work Group $415
  • #30: Implementing a Risk-Based Monitoring Solution: Understanding the Basics of a Sustainable Model $415
  • #31: Machine Learning in Pharmacovigilance $415
  • #33: Quality Tolerance Limits/Issue Management: Taming the Beast of Clinical Development Risk $415
  • #34: Japan Regulatory Environment: Overview of the Organization, Processes, Systems, and Changes Effecting Pharmaceutical Development $415
  • #36: Value Pricing Bootcamp: A Crash Course in How to Use Real World Evidence to Better Measure Outcomes and Evaluate New Innovative Therapies $415
  • #37: Data Visualization in the Life Sciences $415
  • #35: FDA Advisory Committee Purpose and Noninferiority Case Study: Rivaroxaban $415
  • #40: Smart, Innovative Risk-Based Auditing: Shifting the Paradigm $770
  • #42: Back to the Future: Combination Products in the 21st Century $770
  • DIA 2018 Community Service Opportunity $0